Press Releases

Strategic Initiative Expected to Enhance Technological Capabilities, Advance the Practice of Pharmacy & Enable Support of Safe Medication Management Long Island University and Omnicell, Inc. (Nasdaq: OMCL) (Omnicell), a leading provider of...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023....

2022 Total Bookings of $1.054 billion Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion Ended Year with Over 150 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems Year End 2022 Backlog of $1.215...

2022 Total Bookings of $1.054 billion Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion Ended Year with Over 150 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems Year End 2022 Backlog of $1.215...

The first sentence of the second paragraph of the release dated Feb. 15, 2023, has been corrected to replace the dial-in numbers for the earnings call on Tuesday, February 28, 2023. The updated release reads: OMNICELL TO RELEASE FOURTH QUARTER AND...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced that they will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday,...

Advanced Services combine innovative technology, expertise, and intelligence intended to support business and clinical outcomes across all settings of care Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference: Randall Lipps, Omnicell Chairman,...

GAAP and non-GAAP revenues of $348 million G AAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of...

GAAP and non-GAAP revenues of $348 million G AAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of...

GAAP and non-GAAP revenues of $348 million G AAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2022, before market on Wednesday, November 2,...

Summer 2022 Release features new services and solution enhancements designed to improve safety and efficiency and generate value for customers across the continuum of care Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell”), a leading provider of medication...

Advanced Services Business Model Driving Growth Opportunities and Recurring, High Visibility Revenue Well Positioned in Large and Growing Market Segments Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference: Scott Seidelmann, Omnicell Executive Vice...

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that it will host an Investor Day on September 20, 2022 at 1:00 p.m. Eastern Time. The Investor Day...